Oppenheimer Asset Management Inc. Grows Holdings in Grifols, S.A. (NASDAQ:GRFS)

Oppenheimer Asset Management Inc. grew its position in shares of Grifols, S.A. (NASDAQ:GRFS) by 5.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 58,677 shares of the biotechnology company’s stock after purchasing an additional 2,790 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Grifols were worth $521,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of GRFS. Brandes Investment Partners LP boosted its position in Grifols by 8.7% during the second quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company’s stock worth $117,242,000 after acquiring an additional 1,481,924 shares during the last quarter. Armistice Capital LLC grew its position in shares of Grifols by 18.7% in the second quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company’s stock valued at $49,759,000 after purchasing an additional 1,244,000 shares during the period. Capital World Investors increased its stake in Grifols by 4.9% in the first quarter. Capital World Investors now owns 20,749,225 shares of the biotechnology company’s stock valued at $138,605,000 after purchasing an additional 961,700 shares during the last quarter. Highland Peak Capital LLC purchased a new position in Grifols during the second quarter worth about $5,991,000. Finally, Black Creek Investment Management Inc. lifted its position in Grifols by 7.7% during the second quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock worth $77,799,000 after buying an additional 881,155 shares during the period.

Analysts Set New Price Targets

Separately, Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Stock Down 8.2 %

GRFS opened at $8.46 on Wednesday. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a 12-month low of $5.30 and a 12-month high of $12.15. The firm’s fifty day moving average price is $8.88 and its 200 day moving average price is $8.04.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.